15-valent recombinant human papillomavirus vaccine (Hansenula polymorpha, China National Biotec Group)

十五价重组人乳头瘤病毒疫苗（（汉逊酵母，重庆博唯佰泰生物））

Report date: 2025/01/03 20:01:02

Base Information

Drug Name15-valent recombinant human papillomavirus vaccine (Hansenula polymorpha, China National Biotec Group)
Drug Alias NameN/A
ClassificationVaccines > Application > Prophylactic vaccineVaccines > Biological material > Viral vaccineVaccines > Vaccine type > Multivalent vaccine
Mechanisms of ActionImmunostimulants
TargetsNot applicable
Therapy Area/IndicationsNeoplasmsPapillomavirus InfectionsCondylomata Acuminata
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesChongqing Bovax Biopharmaceutical Co LtdShanghai Bovax Biotechnology Co Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesChongqing Bovax Biopharmaceutical Co LtdShanghai Bovax Biotechnology Co Ltd
Inactive CompaniesN/A
Active IndicationsNeoplasmsPapillomavirus InfectionsCondylomata Acuminata
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A